Sign in
Taking people in United StatesPhase 1

Testing VET3-TGI, alone or with atezolizumab, in adults with advanced solid tumors

Tests VET3-TGI, a new treatment, alone or with atezolizumab, in adults with advanced solid tumors.

Key facts

Who runs it
KaliVir Immunotherapeutics
Where
Dallas, Houston, Indianapolis, Los Angeles, Miami, Orange, and Pittsburgh, United StatesSee the 7 sites
Trial code
Registry title
A Study of VET3-TGI in Patients With Solid Tumors
Status
Recruiting
Phase
Phase 1
People taking part
60 people, planned
Started
16 Sept 2024
Expected to end
31 Dec 2027
Type of study
Interventional, 4 groups
Treatments tested
  • VET3-TGI
  • Atezolizumab
Record updated
7 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced solid tumors that cannot be removed by surgery or have spread, and who have run out of other treatment options.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Advanced, unresectable or metastatic solid tumor, confirmed by tissue testing, with disease that can be measured by RECIST 1.1 criteria and at least one tumor that can safely be injected or biopsied.
Earlier treatment
Other treatments meant to remove all of the disease, such as targeted drugs, immunotherapy or chemotherapy, must have failed, not been tolerated or been refused. A washout period applies after earlier systemic therapy.

Main reasons for not taking part

  • Needs blood thinners or anti-platelet drugs that cannot be safely paused for biopsies or injections
  • Brain or spinal fluid cancer spread that has not been fully removed or fully treated with radiation
  • Earlier heart muscle inflammation (myocarditis)
  • Known HIV/AIDS, or active hepatitis B or C infection
  • High-dose immune-suppressing medicine or a major immune weakness, such as an organ transplant

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Have pathologically confirmed, advanced, unresectable, or metastatic solid tumors. Preferred indications include, but are not limited to, breast carcinoma, bladder carcinoma, cervical squamous carcinoma, colorectal carcinoma, esophageal carcinoma, head and neck squamous carcinoma, renal cell carcinoma, ovarian carcinoma, sarcoma, thymoma, and uterine carcinoma
  • Failed, intolerant to, or refused potentially curative treatment options, including but not limited to, standard of care molecularly targeted agents, immunotherapy (e.g., anti -pembrolizumab/PDL1 antibodies), and chemotherapy
  • Measurable disease as per RECIST 1.1 criteria
  • At least one tumor amenable to safe ITu injections and/or biopsies
  • ECOG performance status 0 or 1
  • Demonstrate adequate organ function
  • Must be willing to comply with all protocol procedures and adhere to post-treatment care instructions; Additional Inclusion criteria exist

Who cannot take part

  • Prior systemic therapy washout (dependent upon the therapy)
  • Prior history of myocarditis
  • Receiving high dose immunosuppressive medication or has a significant immunodeficiency (e.g. transplant recipient, etc); Additional Exclusion criteria exist
  • Known HIV/AIDS, active HBV or HCV infection
  • Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies or intra-tumoral injections
  • CNS metastases and/or carcinomatous meningitis that have not been completely resected or completely irradiated

Where in United States

  • Mary Crowley Cancer ResearchDallas, United StatesContact: Minal Barve, MDTaking people
  • University of Texas - MD Anderson Cancer CenterHouston, United StatesContact: Siqing Fu, MD, PhD (principal investigator)Taking people
  • Community Health NetworkIndianapolis, United StatesContact: Bert O'Neil, MD (principal investigator)Taking people
  • USC / Norris Comprehensive Cancer CenterLos Angeles, United StatesContact: Xiomara Menendez, RNTaking people
  • University of MiamiMiami, United StatesContact: Jaime Merchan, MD (principal investigator)Taking people
  • UC Irvine HealthOrange, United StatesContact: Edward Uchio, MD (principal investigator)Taking people
  • UPMC Hillman Cancer CenterPittsburgh, United StatesContact: Yana Najjar, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

The 4 groups in the trial

  • Group A: VET3-TGI alone intratumoralTreatment being tested

    Dose escalation of VET3-TGI alone administered by direct injection into tumor(s) x 4. Booster injections of VET3-TGI are permitted for up to 2 years.

    Treatment: VET3-TGI

  • Group B: VET3-TGI intratumoral in combination with atezolizumabTreatment being tested

    VET3-TGI will be given in combination with atezolizumab at the highest tolerated dose from Group A. Atezolizumab will be administered via intravenous (IV) infusion for up to 2 years.

    Treatment: VET3-TGI and Atezolizumab

  • Group C: VET3-TGI alone intravenousTreatment being tested

    Dose escalation of VET3-TGI alone administered by IV infusion x 6. Booster infusions of VET3-TGI are permitted for up to 2 years.

    Treatment: VET3-TGI

  • Group D: VET3-TGI intravenous in combination with atezolizumabTreatment being tested

    VET3-TGI will be given in combination with atezolizumab at the highest tolerated dose from Group C. Atezolizumab will be administered via intravenous (IV) infusion for up to 2 years.

    Treatment: VET3-TGI and Atezolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors
Plain-language title
Testing VET3-TGI, alone or with atezolizumab, in adults with advanced solid tumorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
7 April 2026